A Randomized, Partially Observer-blind, Dose-escalation, Phase I/II Trial Evaluating the Safety and Immunogenicity of Investigational RNA-based Mpox Vaccine Candidates

BioNTech SE16 个研究点分布在 2 个国家目标入组 96 人开始时间: 2023年9月21日最近更新: 2026年9月15日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: BioNTech SE
入组人数: 96
试验地点: 16
主要终点: SSA, SSB, and SSD - Proportion (%) of participants reporting solicited local reactions at the injection site (pain, erythema/redness, induration/swelling)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验相关资讯

研究概览

简要总结

This was a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox (mpox).

This study was originally planned to include four substudies, i.e., substudy A (SSA), substudy B (SSB), substudy C (SSC), and substudy D (SSD). Sponsor decided not to conduct SSC, thus three substudies (SSA, SSB, and SSD) were conducted.

In SSA and SSB, dosing started with an initial sentinel group, followed by the expansion cohort. In SSD, dosing was initiated after the interim analysis of SSA and SSB 1-month post-Dose 2 safety, reactogenicity, and immunogenicity data was received.

This study was initially planned to investigate two vaccine candidates (the quadrivalent BNT166a and the trivalent BNT166c). The sponsor decided to not activate the groups with BNT166c.

详细描述

Substudy A was an open-label, dose-escalation, Phase I substudy to assess the reactogenicity, safety, and immunogenicity of up to three dose levels of the multivalent vaccine candidate BNT166a in 48 healthy participants with no prior history of known or suspected smallpox vaccination (vaccinia-naïve participants).

Substudy B was a one group, open-label, Phase I substudy to assess the reactogenicity, safety and immunogenicity of the multivalent vaccine candidate BNT166a in 16 healthy participants with prior history of smallpox vaccination (vaccinia-experienced).

Substudy D was a one group, open-label, Phase IIa substudy to assess the reactogenicity, safety, and immunogenicity of one dose level of BNT166a in ~32 healthy participants with no prior history of known or suspected smallpox vaccination (i.e., vaccinia-naïve participants). SSD was initiated after the interim analysis of SSA and SSB safety, reactogenicity, and immunogenicity data.

The duration of study participation was ~ 14 months per participant in all of the substudies.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Sequential
主要目的: Prevention
盲法: None

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•(applicable to all substudies unless otherwise specified):
•Had given informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
•Were willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study, including the prohibited concomitant medications. This included that they were able to understand and follow study-related instructions.
•SSA and SSD only: Were 18 through 45 years of age (inclusive) at the time of informed consent.
•SSB only: Were 50 through 65 years of age (inclusive) at the time of informed consent.
•Had a body mass index over 18.5 kg/m^2 and under 30 kg/m^2 and weighed at least 50 kg at Visit
•Were healthy, in the clinical judgment of the investigator based on volunteer-reported medical history data, physical examination, 12-lead electrocardiogram (ECG), vital signs, and clinical laboratory test results.
•SSA and SSD only: Had no prior history of known or suspected smallpox vaccination and no detectable smallpox vaccination characteristic scar (vaccinia-naïve participants).
•SSB only: Had a history of prior smallpox vaccination (i.e., are vaccinia-experienced), determined based on medical records and/or presence of smallpox vaccination characteristic scar. The most recent smallpox vaccination was received before
•Agreed not to enroll in another study with an investigational medicinal product starting from Visit 0 and until the end of this study.
•Negative human immunodeficiency virus (HIV)-1 and HIV-2 antigen/antibody blood test result at Visit
•Negative Hepatitis B surface antigen and negative core antibodies test results and negative anti Hepatitis C virus antibodies (anti-HCV), or negative Hepatitis C virus (HCV) polymerase chain reaction test result if the anti-HCV was positive at Visit
•Volunteers of childbearing potential (VOCBP) must not have been pregnant. VOCBP and men who were sexually active with partners of childbearing potential and their sexual partners born female should have used a highly effective form of contraception from at least 28 days prior to Dose 1 up to at least 90 days after receiving the last dose of study treatment, and should have agreed not to donate eggs (ova, oocytes) or sperm.

排除标准

•(applicable to all substudies unless otherwise specified):
•History of mpox, smallpox or vaccinia infection based on volunteer-reported medical history.
•Pregnant, breastfeeding, were planning pregnancy or were planning to father children starting from Visit 0 and continuously until 90 days after receiving Dose
•History of known or suspected severe adverse reaction including allergic reaction (e.g., anaphylaxis) to vaccines or to vaccine components such as lipids.
•Current or history of the following medical conditions at Visit 0 or Visit 1:
•Uncontrolled, moderate or severe asthma; asthma severity as defined in the US National Asthma Education and Prevention Program Expert Panel report
•Chronic obstructive pulmonary disease.
•Diabetes mellitus type 1 or type 2, including cases controlled with diet alone (Not excluded: history of isolated gestational diabetes).
•Hypertension: If a person had hypertension, excluded for blood pressure that was not well controlled. Well controlled blood pressure was defined as consistently <=140 mm Hg systolic and <=90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must have been <150 mm Hg systolic and <100 mm Hg.
•Systolic blood pressure >=150 mm Hg or diastolic blood pressure >=100 mm Hg.
•Malignancy, excluding localized basal or squamous cell cancer.
•Cardiovascular diseases, (e.g., myocarditis, pericarditis, coronary heart disease, myocardial infarction, congestive heart failure, cardiomyopathy or clinically significant arrhythmias, stroke or transient ischemic attack).
•Bleeding disorders (e.g., factor deficiency, coagulopathy, or platelet disorder).
•Seizure disorder: History of seizure(s) within past 3 years; used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
•Estimated glomerular filtration rate <60 mL/min/1.73 m^
•Chronic liver disease.
•Schizophrenia, major depressive disorder, suicidal ideation. Such psychiatric illnesses, as bipolar disorder, autism and attention deficit-hyperactivity disorder that at the discretion of the investigator could interfere with participation and follow-up as outlined by the study.
•Current or history of the following diseases associated with immune dysregulation:
•Known or suspected immunodeficiency.
•History of solid organ or bone marrow transplantation.
•Asplenia: any condition resulting in the absence of a functional spleen.
•Currently existing or history of any autoimmune disease.
•SSA and SSB: At Visit 0, any screening hematology and/or blood chemistry laboratory value that met the definition of a Grade >=1 abnormality (according to the FDA toxicity grading scale; see separate exclusion criteria for bilirubin and troponin I). Individuals with any stable Grade 1 abnormalities had been considered eligible at the discretion of the investigator. A stable Grade 1 laboratory abnormality was defined as the value which was <= Grade 1 upon repeated testing on a second sample from this individual during the screening period (prior to Visit 1). Individuals with abnormal but not clinically significant parameters not included in the FDA toxicity guidance might have been considered eligible at discretion of investigator.
•SSD only: At Visit 0, any screening hematology and/or blood chemistry laboratory value (according to the FDA toxicity grading scale) that met the definition of a Grade >=2 abnormality; individuals with clinically non-significant Grade 1 abnormalities may be considered eligible at the discretion of the investigator. Individuals with abnormal but clinically non-significant parameters not included in the FDA toxicity guidance might have been considered eligible at the discretion of the investigator. See separate exclusion criteria for bilirubin and troponin I.
•Abnormal total bilirubin at Visit
•Note: inclusion of volunteers with bilirubin <=1.25 upper limit of normal (ULN) if due to Gilbert's syndrome was allowed.
•Any abnormal troponin I value at Visit
•A 12-lead ECG at Visit 0 which was consistent with probable or possible myocarditis/pericarditis or which demonstrated clinically relevant abnormalities that may have affected participant safety or are otherwise clinically significant findings (e.g., complete left bundle branch block, atrioventricular (AV) block, average corrected QT interval by Fridericia (QTcF interval) >450 msec, signs of myocardial infarction, sinus tachycardia (ST) elevation consistent with myocardial ischemia, or serious brady- or tachyarrhythmias).
•Febrile illness (body temperature >=38.0°C) or other acute illness within 48 hours prior to Dose 1 and/or current (if presented at Visit 1, temporary deferral was allowed).
•Participated or had planned participation in strenuous or endurance exercise within 7 days before or after each investigational medicinal product (IMP) administration.
•SSA and SSD only: Vaccination with any Orthopoxvirus-based vaccine including vaccines for prevention of smallpox, disease caused by vaccinia virus or mpox, or vector Orthopoxvirus-based vaccines.
•SSB only: Vaccination for prevention of mpox or disease caused by vaccinia virus, or with vector Orthopoxvirus-based vaccine. Vaccination for prevention of smallpox done in or after
•Any vaccination within 28 days before Dose
•Seasonal inactivated influenza vaccine was allowed, however, it should have been administered at least 14 days before IMP administration.
•Any non-study IMP within 28 days or five half-lives (whichever was longer) before Dose
•Blood/plasma products and/or immunoglobulins within 120 days before Dose
•Allergy treatment with antigen injections within 14 days before Dose
•Immunosuppressive therapy, including corticosteroids, or radiotherapy within 6 months or five half-lives (whichever is longer) before Dose
•If systemic corticosteroids were administered short term (<=14 days, at a dose of <=20 mg/day of prednisone or equivalent) for treatment of an acute illness, individuals should have been enrolled in the study only after corticosteroid therapy was discontinued for at least 28 days before Dose
•Intraarticular, intrabursal, or topical (skin or eyes) corticosteroids were permitted.
•Had a history of alcohol abuse within 1 year before Visit 0 or had a history of substance abuse within the past 5 years before Visit
•Were vulnerable individuals as per international council for harmonisation (ICH) E6 definition, i.e., were individuals whose willingness to volunteer in a clinical study might have been unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.

研究组 & 干预措施

SSA: BNT166a 30 mcg

Experimental

Participants received two intramuscular doses of the multivalent RNA-based vaccine BNT166a at Visit 1 (Day 1) and at Visit 5 (Day 31) for active immunization against monkeypox.